<SEC-DOCUMENT>0000912282-16-000922.txt : 20161215
<SEC-HEADER>0000912282-16-000922.hdr.sgml : 20161215
<ACCEPTANCE-DATETIME>20161215172526
ACCESSION NUMBER:		0000912282-16-000922
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161215
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161215
DATE AS OF CHANGE:		20161215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AntriaBio, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54495
		FILM NUMBER:		162054514

	BUSINESS ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		1450 INFINITE DRIVE
		CITY:			LOUISVILLE
		STATE:			CO
		ZIP:			80027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>antriabio8k_121516.htm
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Dorsey & Whitney LLP
    Document created using EDGARfilings PROfile 4.2.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div><br>
<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">UNITED STATES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">WASHINGTON, D.C. 20549</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">FORM 8-K</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">CURRENT REPORT</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Date of Report (Date of earliest event reported): December 15, 2016</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center"><u>ANTRIABIO, INC.</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Name of registrant in its charter)</div>

<div><br>
</div>

<table id="zcea4fdab8d3346eca0e3029c6226d424" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 37.09%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: "><u> </u>

<div style="TEXT-ALIGN: center"><u>Delaware</u></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 27.43%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: "><u> </u>

<div style="TEXT-ALIGN: center"><u>000-54495</u></div>
</td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 35.48%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; FONT-STYLE: normal; BORDER-BOTTOM-COLOR: "><u> </u>

<div style="TEXT-ALIGN: center"><u>27-3440894</u></div>
</td>
</tr>

<tr>
<td style="WIDTH: 37.09%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(State or jurisdiction</div>
</td>
<td style="WIDTH: 27.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(Commission File</div>
</td>
<td style="WIDTH: 35.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(IRS Employer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 37.09%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">of incorporation or</div>
</td>
<td style="WIDTH: 27.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Number)</div>
</td>
<td style="WIDTH: 35.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Identification No.)&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 37.09%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">organization)&#160;</div>
</td>
<td style="WIDTH: 27.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 35.48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">1450 Infinite Drive</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">Louisville, CO 80027</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;(Address of principal executive offices)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">(303) 222-2128</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;(Registrant's telephone number)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center">&#160;(Former name or former address, if changed since last report)</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

<div><br>
</div>

<table id="zbed903798fb8403fac117b10248f7438" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.66%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 96.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="zde00847aa0584a6bab97f22844668f26" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.66%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 96.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="z80d59d9e694348e49f1f22cc808043b7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.66%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 96.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
</td>
</tr>
</table>

<div><br>
</div>

<table id="z66e1a9b5c9a74aefacd3730ad2f7d618" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.66%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#9744;</div>
</td>
<td style="WIDTH: 96.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#160;</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: right">&#160;</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 7.01. Regulation FD Disclosure.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">On December 15, 2016, we issued the press release attached hereto as Exhibit 99.1.&#160;&#160;In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in the press release is deemed to be &#8220;furnished&#8221; and shall not be deemed to be &#8220;filed&#8221; for purposes of the Securities Exchange Act of 1934, as amended.&#160;&#160;The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">Item 9.01 Financial Statements and Exhibits</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="z7f54e45efe964f8483b73c3decd76404" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9.15%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">EXHIBIT</div>
</td>
<td style="WIDTH: 90.85%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">DESCRIPTION</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.15%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">99.1</div>
</td>
<td style="WIDTH: 90.85%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Press Release of AntriaBio, Inc. dated December 15, 2016 **</div>
</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">** The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</div>

<div><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">SIGNATURES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="z3d5c587496e947d4a4f9b1ca3516f35e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">ANTRIABIO, INC.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 48%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.34%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.66%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 48%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
<td style="WIDTH: 5.34%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.66%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">DATE:&#160;&#160;December 15, 2016</div>
</td>
<td style="WIDTH: 5.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">By:</div>
</td>
<td style="WIDTH: 46.66%; VERTICAL-ALIGN: top; BORDER-BOTTOM: black 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">/s/ Morgan Fields&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 48%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 5.34%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>
</td>
<td style="WIDTH: 46.66%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Morgan Fields</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Chief Accounting Officer</div>
</td>
</tr>
</table>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="MARGIN-BOTTOM: 10pt"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">EXHIBIT INDEX</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<table id="za87be316f01c411cadded147930ca16a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 9.15%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">EXHIBIT</div>
</td>
<td style="WIDTH: 90.85%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left">DESCRIPTION</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.15%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">99.1</div>
</td>
<td style="WIDTH: 90.85%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Press Release of AntriaBio, Inc. dated December 15, 2016 **</div>
</td>
</tr>

<tr>
<td style="WIDTH: 9.15%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="WIDTH: 90.85%; VERTICAL-ALIGN: middle; BACKGROUND-COLOR: #ffffff">&#160;</td>
</tr>
</table>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">** The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div><br>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99_1.htm
<DESCRIPTION>PRESS RELEASE DATED DECEMBER 15, 2016
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: Dorsey & Whitney LLP
    Document created using EDGARfilings PROfile 4.2.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div style="FONT-WEIGHT: bold; TEXT-ALIGN: right">EXHIBIT 99.1</div>

<div style="TEXT-ALIGN: right">&#160;</div>

<div style="TEXT-ALIGN: right"><img src="image00001.jpg"></div>

<div style="TEXT-ALIGN: right">&#160;</div>

<div>
<div style="FONT-SIZE: 12pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center">AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock</div>

<div style="BACKGROUND-COLOR: #ffffff"><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">LOUISVILLE, CO &#8211; December 15, 2016 &#8211; </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: bold; FONT-STYLE: normal"><u>AntriaBio, Inc.</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(&#8220;AntriaBio&#8221; or the &#8220;Company&#8221;) (OTCQB: ANTB), a biopharmaceutical corporation focused on developing novel extended release therapies, </font>announced today that it has commenced an offer to amend (the &#8220;Offer to Amend&#8221;) certain warrants to purchase 16,450,915 shares of AntriaBio common stock originally issued by AntriaBio. The exercise price of each Amended Warrant will be reduced to $1.65 per share and the expiration date of each amended warrant will be extended to the earlier of January 31, 2020 or the twentieth day after the date on which an Acceleration Notice is given. The Offer to Amend commenced today and will expire, unless extended, at 4:00 p.m. Mountain Time on Tuesday, January 31, 2017. Amendment of warrants must be made prior to the expiration of the Offer to Amend and may be withdrawn at any time prior to the expiration of the Offer to Amend.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Eligible warrants (&#8220;Eligible Warrants&#8221;) in the Offer to Amend include:</div>

<div><br>
</div>

<div>
<table id="z8d61f2fc31644d9685afc8e1ac4a0381" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 118,753 shares of common stock at an exercise price of $1.89 per share issued on December 23, 2013;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z499de45ca8ee45838011034ea07b9a7b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 8,334 shares of common stock at an exercise price of $1.89 per share issued on December 31, 2013;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z2eb237c4ac3b4eeeb86bd44ae6baa2e1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 98,172 shares of common stock at an exercise price of $1.89 per share issued on January 15, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z40917a91da0f45eea75bc932ea8b727a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 6,287,671 shares of common stock at an exercise price of $2.34 per share issued on March 31, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z4bbc314fa85343aeaeb3c8e62cd5cff2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 3,249,717 shares of common stock at an exercise price of $2.03 per share issued on March 31, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z51eb97b322c14893b5c78cebb293742a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 426,008 shares of common stock at an exercise price of $2.25 per share issued on March 31, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z271be69acedf4ab4812e0698568519cc" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 114,492 shares of common stock at an exercise price of $1.38 per share issued on March 31, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z7df243bd21744ac0bdfca4570cccf2ef" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 106,847 shares of common stock at an exercise price of $1.17 per share issued on March 31, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zd5f79ab38ef44c7ebda00f63f279a743" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 1,782,783 shares of common stock at an exercise price of $2.50 per share issued on November 28, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z384b88c22ccd4cdbbbfc4ea7cd154d90" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 1,960,774 shares of common stock at an exercise price of $2.50 per share issued on December 31, 2014;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="zc4129bb8f16548ad8e0f1f7e127f6bff" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 897,004 shares of common stock at an exercise price of $2.50 per share issued on February 18, 2015;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z515179aa2fca444ca6a87d7c8d293020" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 327,921 shares of common stock at an exercise price of $2.50 per share issued on February 23, 2015;</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z5d0ee52333a443408cdf50bf0481ae87" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 307,798 shares of common stock at an exercise price of $2.50 per share issued on March 31, 2015 and</div>
</td>
</tr>
</table>
</div>

<div>
<table id="z55415e8899524146ad6112e2ba58d6b0" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 36pt; VERTICAL-ALIGN: top; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: left; MARGIN-LEFT: 18pt">&#183;</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Warrants to purchase an aggregate of 764,641 shares of common stock at an exercise price of $2.50 per share issued on April 6, 2015.</div>
</td>
</tr>
</table>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The primary purpose of the Offer to Amend is to reduce the exercise price for the Eligible Warrants as well as to provide additional time for warrantholders to exercise their Eligible Warrants. All Eligible Warrants are eligible to be amended pursuant to the Offer to Amend. The Offer to Amend is not conditioned upon a minimum number of Eligible Warrants being tendered. The Offer to Amend is, however, subject to certain customary conditions.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company will amend all Eligible Warrants properly tendered (upon receipt of warrantholder Election Form, Accredited Investor Questionnaire and Warrant Amendment) and not properly withdrawn prior to the expiration of the Offer to Amend as described in the Schedule TO that was filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) and is being distributed to warrantholders.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">None of the Company, its Board of Directors, officers or employees makes any recommendations to warrantholders as to whether to participate in the Offer to Amend.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">This press release is for informational purposes only and is not an offer to purchase or a solicitation of an offer to sell securities. The Offer to Amend described above is made only pursuant to an Offer to Amend on Schedule TO and related exhibits, including the related letter from Nevan C. Elam dated December 15, 2016, the Election Form, the Withdrawal Form, the Accredited Investor </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right"><img src="image00001.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Questionnaire, the Form of Warrant Amendment and other related documents, filed with the SEC. Warrantholders should read the Offer to Amend on Schedule TO, the related letter from Nevan C. Elam dated December 15, 2016, the Election Form, the Withdrawal Form, the Accredited Investor Questionnaire, the Form of Warrant Amendment and related exhibits, as they contain important information about the Offer to Amend. Warrantholders can obtain these documents free of charge from the SEC&#8217;s website at <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: bold; FONT-STYLE: normal"><u>www.sec.gov</u></font>, or by directing a request to Noopur Liffick at <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: bold; FONT-STYLE: normal"><u>investor-relations@antriabio.com</u></font>.<br>
<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> About AntriaBio, Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">AntriaBio is a biopharmaceutical company that develops novel extended release therapies by combining proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. For more information visit:&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>www.antriabio.com</u></font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Forward-Looking Statements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">AntriaBio, Inc. Contact:</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Noopur Liffick<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>VP of Corporate Development<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (650) 549-4175</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: left"><u>investor-relations@antriabio.com</u></div>

<div><br>
</div>

<div><br>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">Source: AntriaBio Inc.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  U /@# 2(  A$! Q$!_\0
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MZ-GYQ]0 17*_#WP?XR\.W&J:?#;VMK'>%5;4FD#-&HSDHHZD@\9Q@UU'Q(\
MR:KX)LM+T#:LEA()(TD;_6\$-EO[Q)SD]3FJ=KHE7LS1^#FD_P!D> -.#C$M
MR#<R9_VNG_CN*N^*/$]M;>!-2UJQEWQB)T@?& SY* C/4;JYSP_9^-=5T6VT
M;6;>VTFPCC6&>XCDW3S1@8VJ 2%)'!;\JE^+GAS5=7\-:?HOAJS0VJ.#(H<(
M%1!A5Y^OZ4K:ZCZ:&3^SOH0MM!N]:F7,][(8XV/4(O7\VS^0KUVLKPII2Z)X
M;T[35QFWA5&]VQ\Q_/-:M3)W=RHJRL>"WP_X3+X]1P_ZRSTY@#W&V+D_FYQ^
M-=A\<M5C'@/4K>TG#2K/%#.J'.S/S8/U 'YUSOASPCXO\->-M7N=.LK.>.]+
MJE[/)\L89]V[:.2?;%=UJ_@>"^\#76A"=FN)R9WNY1EI+C.XNV/4\8[#CM5M
MJZ(2=F4_@;:K;?#FP*XS,\DC$=SN(_D!7%_M ZQ_:&J:5X9LF#R^8))0#_&W
MRHOY$G\172>!X/&&A^'8_#_]C0+-"S+'J$EPIA52<Y*CYB1D\<9]JP?$O@#6
M]/\ &FDZSHELNK&/;)<//(JM+,&)9FST!R,8Z8QVH5N:X._+8]9TE+/1[73=
M&25%E2W"Q1Y^9E0 $X_$?G7*>#Q]L\8ZI=R#YD+XSVRV/Y5O>&=(N[>>XU36
MY(YM8NP%?R_]7;QCI$F>PZD]S53^RKO1_$$VH:?!]IMKC/F1*P5ER<\9Z\_S
MKS\7!N=.=KI/7_,BHG>+Z)G0:O=K8Z7<W+](XR1[GL/SKCOAO9F&&\U.?A&&
MU2?0<L?Y?K6KJ%CJ'B%TBNXC8Z>C;F0L&DD_+@5M7%BG]D26-J!$IB,:8Z+Q
M4.$JU95;:13MYL'%SGS]$<9X'1M3\2W^IR X7)7/8L>/R&:/B5<"XAT\P,'@
M+/\ ,IR,@@5/X;T?6K2WN;!T2U@FDW27 8%]O0A<=SZUNZ_X?AU'1X[.W"Q&
M#!A]!@8P?K7)"A4J825-+5ZN_5W,5"4J+C;4T]-A%OI]M"HP$C5?TKA_B!*^
MH:U8Z9;?,Z]0/[S?_6 _.NECO=42RCA33'-XJ["[.HCR/XLYR1[4S0/#XL;F
M2^O9!<:A*26?LN?3_&NK$1>(@J,%9:7?9?YFM1.HE!;&U9P+;6L,"?=C0(/P
M%%2T5WI65D= 4444P C/6@ #H *** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
